An analysis of all US Food and Drug Administration (FDA) approvals for protein-based assays through 2008 reveals 109 unique protein targets in plasma or serum, as well as 62 additional tests for peptides, protein posttranslational modifications, protein complexes, autoantibodies against endogenous proteins and blood cell proteins. A further 96 unique protein targets are assayed in plasma by laboratory-developed tests available for clinical use in the US, yielding a total of 205 proteins that include products of approximately 211 genes (excluding immunoglobulins). These tests provide quantitative measurements for approximately 1% of the human protein gene products, defining a practical clinical plasma proteome. The rate of introduction of new protein analytes has remained essentially flat over the past 15 years, averaging 1.5 new proteins per year (median of 1 per year). This rate falls far short of that needed to support projected medical needs and indicates serious deficiencies in the protein biomarker pipeline, from which no proteomicsdiscovered analytes have yet emerged.
Proteins are molecular machines responsible for performing most catalytic and structural, as well as many signaling, functions of living organisms. Measurements of proteins thus offer abundant opportunities to detect and characterize molecular malfunctions related to disease and its progression as manifested in the individual patient. Given that blood and its liquid component (plasma or, after clotting, serum) are the overwhelmingly predominant clinical specimens available for routine molecular analysis, molecules present in blood have the widest diagnostic potential. Among these, proteins frequently have the greatest clinical significance. Proteins provide a broad picture of patient phenotype (current status), rather than indicating unchanging probabilistic risks that can be inferred from sequence analysis of genomic DNA (e.g., from white blood cells). Analysis of plasma mRNA (1 ) , although capable of detecting a range of fetal and other phenotypic abnormalities, has not yet achieved widespread use in diagnostics. Likewise circulating tissue cells, useful in cell-based assays, have been observed in specific cancers (2 ) but have yet to be exploited in routine diagnostic medicine. Small molecule metabolites are abundant in plasma, but, being the products rather than the mechanisms of life processes, reveal a limited range of enzymatic and filtration defects. Thus among the classes of molecular analytes, proteins provide a unique combination of practical accessibility and broad clinical significance.
The clinical chemistry of proteins has already achieved fundamental importance in medicine. Existing protein tests provide a spectrum of clinical information, including definitive diagnosis of acute events (e.g., cardiac troponin released into blood after a myocardial infarction), prediction of disease risk [Creactive protein (CRP) 1 increases in coronary disease] and detection of disease recurrence (thyroglobulin in metastatic thyroid cancer after thyroid removal). These successes have raised hopes for new and improved clinical diagnostic tests for many disease indications and, as a result, have focused substantial attention on the discovery of novel protein biomarkers. Recent refinements of global protein detection methods, referred to as proteomics, hold out the promise of rapid progress in this area-promise as yet unfulfilled in the form of any widely used clinical test. Considerable discussion in the research community has identified several factors limiting progress in identifying new clinical bio-markers, including the lack of an effective technology platform to verify candidate markers in large sample sets (3 ), the difficulty of securing access to welldesigned clinical sample sets without significant bias (4 ), the absence of an organized biomarker development pipeline (5, 6 ) , and finally, the absence of anything approaching a useful theory of biomarkers. This last point exposes the totally empirical nature of biomarker research and suggests a sobering comparison with the pharmaceutical industry, in which progress is slowing despite research funding at more than 100 times the level of protein diagnostics.
In confronting such difficulties, it is instructive to survey past experience in the relevant field (clinical chemistry Hortin et al. (8 ) or from SwissProt (molecular weight). Five classes of protein analytes were assigned by inspection: proteins that act in plasma (at least 1 function in circulation), immunoglobulins, receptor ligands (e.g., hormones), tissue leakage (e.g., cardiac troponins), and aberrant secretions (e.g., cancer markers). Given the numbers of tests surveyed and the selection of protein analytes by inspection, there is significant potential for error or inexactness in the assembled data. Any such errors are the responsibility of the author, who would be grateful for material corrections.
FDA-Cleared or -Approved Tests for Proteins in Plasma or Serum
The primary objective of this analysis was to investigate the number and character of protein analytes currently measured by IVD tests, beginning with those that have been cleared or approved by the FDA. For this purpose, I used a rather restrictive definition of protein, resulting in selection of 109 unique protein analytes ( 109) . Costs for the FDA-approved assays, using average 2008 Medicaid reimbursement rate as a proxy, vary by more than 10-fold, from $9 for albumin to $122 for her-2/neu protein, with an average cost of $29 (median $25). Average immunoassay cost across these analytes is $31, whereas average enzyme assay cost is $16, reflecting the age and overall simplicity of enzyme assays. There appears to be little if any relationship between test cost and the protein's normal concentration or the date of the test's approval.
The largest subset of the 109 protein analytes (45%) carry out a known function in plasma other than antigen binding, and a further 6% are immunoglobulins (Fig. 1) . Hence a total of 51% of assays measure proteins that can be considered to carry out their normal functions in plasma, adopting a previous classification (10 ) . Tissue leakage products (25%) and receptor ligands (hormones, etc.; 18%) constitute the other major classes, with the remainder comprising aberrant secretions (mainly tumor markers; 6%).
Pace of Introduction of New Tests
Of the 109 unique FDA-approved protein tests as defined here, 87 (80%) were introduced before 1993 and 22 (20%) in the last 15 years (Fig. 2) . The average rate of FDA approval of new protein-based tests over the last 15 years is thus approximately 1.5 new tests per year (median of 1 per year), a rate that appears to have been essentially constant over this period. Although an earlier analysis through 2002 (10 ) suggested a substantial decline, the present reanalysis extending through the end of 2008 indicates only a slight downward trend. The current rate of introduction does seem to be less than pre-1993, given that most pre-1993 tests were probably introduced in the prior 15-year period (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) , the heyday of immunoassay development with monoclonal antibodies): 87 tests introduced between 1977 and 1993 would yield an average rate of 5.8 new tests per year.
Test Versions
Approximately 90% of all protein tests ever formally cleared or approved are still in active use: 98 of the 109 tests are offered by 1 of the 3 reference laboratories surveyed, and 85 (78%) are offered by all 3. A some- Individual protein analytes appear multiple times in the database, each the result of a CLIA approval and categorization (here called an "entry"). Repeat entries can indicate that a new assay has been developed (e.g., by a new vendor), that an assay has been improved or changed category, that an existing assay has been implemented on a new instrument platform, or even that the vendor has changed its name. Hence the absolute count of assay entries is not directly interpretable in terms of the number of distinct assays that have been made to detect the analyte, but is used here as a proxy for the amount of development activity around a given protein analyte. In aggregate, the 109 proteins tests have been entered a total of 7603 times, with 2949 of these entries submitted by major instrument platform vendors.
CRP has been entered most frequently (378 entries), perhaps because of its dual use (low-sensitivity test for inflammation and high-sensitivity for cardiovascular risk). Nine other tests have been entered Ͼ200 times, including 6 enzymes [amylase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), ␥-glutamyltransferase (GGT), lipase, and creatine kinase-MB (CK-MB), here considered a protein complex] and 3 high-/medium-abundance plasma proteins (albumin, ferritin, and fibrinogen). A further 21 tests have been entered between 101 and 200 times, 37 tests (sTfR 1997; 18) . Immunoassays predominate in recent tests: only 1 of these 7 involves an enzyme (pancreatic amylase), and even in that case, the test usually involves an antibody to achieve isoenzyme specificity.
Under CLIA regulations, tests are classified in 3 categories as to complexity: high, moderate, and waived. Of the 109 protein analytes, 95 have a highcomplexity version (presumably introduced first), and of these, 54 have a moderate-complexity version of the same date (i.e., 1993). In 17 cases, a moderate version was introduced in the last 15 years after a preexisting high version, and in 12 cases a moderate test was introduced without a high-complexity precursor. A total of 9 analytes have waived versions (considered simple and accurate to use, in each case approved in the last 15 years and following after Ͼ100 approved high-and moderate-complexity versions. The waived analytes include 5 enzymes (GGT, AST, ALT, amylase, and alkaline phosphatase), 3 hormones [thyroid-stimulating hormone (TSH), luteinizing hormone (LH), folliclestimulating hormone (FSH)], and albumin.
Other FDA-Cleared or -Approved Tests
A further 62 tests involving human proteins have been cleared or approved by the FDA (online Supplementary Table 2 , Fig. 3 ). Autoantibodies against human proteins formed the largest subset (20 tests; numerous allergen tests were excluded because they involve IgE against nonhuman protein antigens), some of which are aimed at detecting autoimmune disease (e.g., antiacetylcholine receptor antibodies) and some at detecting autoantibodies known to interfere with immunoassays of the protein target (e.g., antithyroglobulin antibodies (11 )). The second-largest subset involved posttranslational modifications of proteins for which tests exist already in Table 1 (18 tests, of which 6 involve glycosylation and 12 involve proteolytic cleavage and/or cross-linking). These tests demonstrate the clinical potential for PTM-based biomarkers emerging from advanced proteomics studies. Peptides falling beneath the 5-kDa arbitrary cutoff (7 tests), complexes (3 tests), and proteins assayed in blood cells but not in plasma or serum (14 tests) account for the remainder.
Laboratory-Developed Tests for Additional Unique Proteins in Plasma/Serum
A survey of large reference laboratory test menus and the published DORA yielded an additional 96 unique protein tests applied to plasma or serum (online Supplementary Table 3 ). A pool of 3 reference laboratories offered tests for 62 unique proteins in addition to 98 of the 109 FDA-approved analytes. DORA listed a further 34 unique protein tests (in addition to 31 also offered by the reference labs), approximately half of which consist of cytokines and growth factors widely measured in cell biology studies. The overall total number of unique proteins measured is 205 (Fig. 4) .
In parallel with these technical advances, 2 major improvements in the use of IVD results may further leverage their clinical (and thus economic) value. The ability to use multiplex panels of specific proteins may significantly improve diagnostic performance through use of protein ratios (giving improved internal standardization) and more sophisticated interpretive algorithms. Perhaps more important, measurement of changes within individual patients over time using periodic sampling (true personalized medicine, with a personal baseline replacing the current populationbased reference interval) allows detection of smaller, and thus earlier, disease-related changes (20 ) . Both of these approaches aim to increase biological signal in relation to noise to increase the clinical relevance of test results, and both require a significant increase in the total volume of protein tests performed in the clinical laboratory.
Time will tell whether a revolution in protein diagnostics lies ahead. Such a possibility has long been discounted given the conservative structure of the IVD industry, its regulatory load, limited venture investment, and the paucity of attractive new markers to date. In fact, there appears to have been no really disruptive change in protein diagnostics since the introduction of immunoassays almost 50 years ago (21 ) . Even so, business as usual no longer appears to be a viable option in the face of current challenges in healthcare delivery. If the tools are at hand to construct a new paradigm, we are fortunate indeed. 
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